These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38839155)

  • 1. Pulse Pressure Response to Inotrope Therapy in Cardiogenic Shock: A Subanalysis of the DOREMI Trial.
    Han J; Di Santo P; Mathew R; Hibbert B; Grinstein J; Belkin MN
    JACC Heart Fail; 2024 Jun; 12(6):1126-1127. PubMed ID: 38839155
    [No Abstract]   [Full Text] [Related]  

  • 2. Inotrope and vasopressor use in cardiogenic shock: what, when and why?
    Hu K; Mathew R
    Curr Opin Crit Care; 2022 Aug; 28(4):419-425. PubMed ID: 35792520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inotropic agents in the treatment of cardiogenic shock.
    Mueller HS
    World J Surg; 1985 Feb; 9(1):3-10. PubMed ID: 3885584
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial.
    Di Santo P; Mathew R; Jung RG; Simard T; Skanes S; Mao B; Ramirez FD; Marbach JA; Abdel-Razek O; Motazedian P; Parlow S; Boczar KE; D'Egidio G; Hawken S; Bernick J; Wells GA; Dick A; So DY; Glover C; Russo JJ; McGuinty C; Hibbert B;
    Crit Care; 2021 Aug; 25(1):289. PubMed ID: 34376218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inotropes and vasopressors use in cardiogenic shock: when, which and how much?
    Levy B; Buzon J; Kimmoun A
    Curr Opin Crit Care; 2019 Aug; 25(4):384-390. PubMed ID: 31166204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between mean arterial pressure and outcomes in patients with cardiogenic shock: insights from the DOREMI trial.
    Parlow S; Di Santo P; Mathew R; Jung RG; Simard T; Gillmore T; Mao B; Abdel-Razek O; Ramirez FD; Marbach JA; Dick A; Glover C; Russo JJ; Froeschl M; Labinaz M; Fernando SM; Hibbert B;
    Eur Heart J Acute Cardiovasc Care; 2021 Oct; 10(7):712-720. PubMed ID: 34382063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current theories on the treatment of cardiogenic shock].
    Zochowski RJ; Jarecki M; Radowicka A
    Kardiol Pol; 1981; 24(4):315-22. PubMed ID: 7026862
    [No Abstract]   [Full Text] [Related]  

  • 8. Levosimendan in cardiogenic shock: the magic drug for every patient?
    Smetana P; Geppert A
    Crit Care Med; 2007 Dec; 35(12):2862-4. PubMed ID: 18043208
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock.
    Lewis TC; Aberle C; Altshuler D; Piper GL; Papadopoulos J
    J Cardiovasc Pharmacol Ther; 2019 Mar; 24(2):130-138. PubMed ID: 30175599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopressor and Inotrope Use in Canadian Emergency Departments: Evidence Based Consensus Guidelines.
    Djogovic D; MacDonald S; Wensel A; Green R; Loubani O; Archambault P; Bordeleau S; Messenger D; Szulewski A; Davidow J; Kircher J; Gray S; Smith K; Lee J; Marc Benoit J; Howes D
    CJEM; 2015 Feb; 17 Suppl 1():1-16. PubMed ID: 26067924
    [No Abstract]   [Full Text] [Related]  

  • 11. Review article: inotrope and vasopressor use in the emergency department.
    Senz A; Nunnink L
    Emerg Med Australas; 2009 Oct; 21(5):342-51. PubMed ID: 19694785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inotropes.
    Francis GS; Bartos JA; Adatya S
    J Am Coll Cardiol; 2014 May; 63(20):2069-2078. PubMed ID: 24530672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressor and inotrope use in Canadian emergency departments: evidence based consensus guidelines.
    Djogovic D; MacDonald S; Wensel A; Green R; Loubani O; Archambault P; Bordeleau S; Messenger D; Szulewski A; Davidow J; Kircher J; Gray S; Smith K; Lee J; Benoit JM; Howes D
    CJEM; 2015 Jan; 17(1):1-2. PubMed ID: 25961083
    [No Abstract]   [Full Text] [Related]  

  • 14. [Stimulating and hypobiotic therapy in cardiogenic shock].
    Bobrov VA; Shved NI; Sherman DM
    Lik Sprava; 1994; (5-6):7-12. PubMed ID: 7831916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of levosimendan for cardiogenic shock in a patient with the apical ballooning syndrome.
    De Santis V; Vitale D; Tritapepe L; Greco C; Pietropaoli P
    Ann Intern Med; 2008 Sep; 149(5):365-7. PubMed ID: 18765717
    [No Abstract]   [Full Text] [Related]  

  • 16. [Impact of the intra-aortic balloon pump in the mortality due to cardiogenic shock secondary to acute myocardial infarction].
    Arias EA; González-Chon O; García-López SM; Chacón MA; Noriega-Iriondo F; Vega RE; Chávez-Tapia NC
    Arch Cardiol Mex; 2005; 75(3):260-6. PubMed ID: 16294814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant levosimendan and esmolol infusion in ischaemic cardiogenic shock.
    Guarracino F; Landoni G; Baldassarri R; Nobile L; Stefani M
    Br J Anaesth; 2010 Mar; 104(3):388-9. PubMed ID: 20150349
    [No Abstract]   [Full Text] [Related]  

  • 18. [Levosimendan for treatment of heart failure].
    Yasumura Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():169-72. PubMed ID: 17571380
    [No Abstract]   [Full Text] [Related]  

  • 19. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.
    Russ MA; Prondzinsky R; Christoph A; Schlitt A; Buerke U; Söffker G; Lemm H; Swyter M; Wegener N; Winkler M; Carter JM; Reith S; Werdan K; Buerke M
    Crit Care Med; 2007 Dec; 35(12):2732-9. PubMed ID: 17893627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of levosimendan in Takotsubo-related cardiogenic shock.
    Antonini M; Stazi GV; Cirasa MT; Garotto G; Frustaci A
    Acta Anaesthesiol Scand; 2010 Jan; 54(1):119-20. PubMed ID: 19961441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.